title: Schizoaffective disorder: a review of current research themes and pharmacological management.
abstract: Despite a clear recognition of the existence of patients with co-morbid psychotic and mood symptoms, many studies conclude that schizoaffective disorder as a distinct diagnosis does not exist. Regardless of one's opinion on schizoaffective disorder, psychiatrists remain dependent on phenomenological descriptions for diagnosing psychiatric disorders, and these phenomenological criteria are also used for clinical trial entry. On the other hand, many psychiatrists prescribe for specific target symptoms and do not always rigidly follow diagnostic systems and, moreover, there have been very few trials that have specifically studied schizoaffective disorder. Despite recent intriguing work in epidemiology, genetics, neurocognition and electrophysiology, the diagnosis of schizoaffective disorder remains controversial. Taken together, these studies suggest that even if schizoaffective disorder exists as a separate diagnosis, it may not be useful clinically due to considerable variation in the general use of this term. It is possible that diagnostic criteria in the future will include genetic, imaging and electrophysiological components, and that this will allow for better differentiation of disease states among the heterogeneous pool of patients currently believed to have schizophrenia, schizoaffective disorder or bipolar disorder. Although it is likely that most, if not all, antipsychotics are effective for schizoaffective disorder, given recent regulatory approval of a specific antipsychotic agent for the acute treatment of schizoaffective disorder, greater attention is now being focused on the entity of schizoaffective disorder and potential treatment decisions. However, based on the limited extant evidence, it is not yet possible to make definitive treatment recommendations for schizoaffective disorder. Additional clinical trials that include other antipsychotics, mood stabilizers and antidepressants are desirable and necessary before clear and comprehensive evidence-based treatment recommendations can be made.
authors.affiliation: Schizophrenia Research Center, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA. jkantrowitz@nki.rfmh.org
authors.forename: Joshua T
authors.initials: JT
authors.lastname: Kantrowitz
authors.forename: Leslie
authors.initials: L
authors.lastname: Citrome
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D015897:Comorbidity; D004359:Drug Therapy, Combination; D006801:Humans; D024821:Metabolic Syndrome / Q000453:epidemiology*; D009369:Neoplasms / Q000453:epidemiology*; D011618:Psychotic Disorders / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents